Sequent Scientific Ltd. is underperforming compared to its peers across key financial metrics, particularly in profitability and valuation. Its high PE ratio and negative ROE indicate significant challenges, while several peers demonstrate strong growth and profitability metrics, positioning them as more attractive investments.

• • Sequent Scientific Ltd. has the highest PE ratio at 269.93 and negative ROE (-4.85), indicating overvaluation and poor returns.
• • Sun Pharma leads in profitability metrics with a ROE of 16.13% and a PE of 87.59, reflecting strong market performance.
• • Divi's Laboratories has the lowest revenue growth over three years at -77.59% and is also highly valued with a PE of 73.20.
• • Cipla and Dr. Reddy's Laboratories show balanced growth and solid profitability with low PE ratios, making them attractive picks.
• • Sequent's high debt-equity ratio (0.7791) combined with negative profitability makes it a financially risky investment.